What is your approach to adjuvant endocrine therapy in hormone receptor positive male breast cancers?

Tamoxifen should be the standard adjuvant endocrine therapy for ER+ breast cancer in men. There has been talk intermittently about aromatase inhibitor (AI) use as alternative endocrine therapy, and I would not recommend the use of AIs in this setting. Data is limited, with the one study comparing ou...

I agree that tamoxifen remains the standard adjuvant therapy (including extended therapy for higher risk cases), and if tamoxifen is contraindicated, GnRH agonist/antagonist plus aromatase inhibitor as recommended by the ASCO Guidelines for male breast cancer (Hassett et al., PMID 32058842).